RCS - Diaceutics PLC - Expansion of PMx Commercialization Partnership

DiaceuticsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250717:nRSQ3842Ra&default-theme=true

RNS Number : 3842R  Diaceutics PLC  17 July 2025

Diaceutics PLC

 

Diaceutics Expands PMx Commercialization Partnership Following Early Success

New York, Belfast and London, 17 July 2025 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, today announces the expansion of
its PMx commercialization partnership contract. This development follows early
success in the collaboration, which was initiated only three months ago, and
reflects our partner's decision to broaden the scope of services delivered
under the agreement.

Ryan Keeling, Chief Executive Officer at Diaceutics, commented: "This
expansion is a testament to the tangible value our PMx solution delivers. It
reflects our partner's confidence in the solution and their commitment to
scaling impact through deeper collaboration. We're proud to be advancing our
mission of getting every patient the right test and the right treatment at the
right time."

The expanded agreement is expected to contribute incremental service revenue
in FY2025 and further strengthens Diaceutics' position as a strategic partner
in the precision medicine ecosystem. The enhanced contract introduces an
additional PMx service, Signal Connect - designed to support healthcare
professionals (HCPs) in deepening awareness and increasing clinical
actionability. Signal Connect combines our groundbreaking DXRX signal data
alerts with expert direct-to-physician engagement services. This service is
particularly impactful in cases involving rare or novel biomarkers, where
timely identification and education are critical to therapeutic consideration
and access to life-changing targeted therapies.

The PMx solution, which integrates multiple services into a single, multi-year
engagement, continues to demonstrate its value as a precision
commercialization solution for biopharma companies. By enabling lean, agile
launches and maximizing patient discovery, PMx delivers commercial impact
which Diaceutics believes to be at with a third of the cost of traditional
commercialization.

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

About Reach Announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRARFMRTMTIBBTA